| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6241933 | Respiratory Medicine | 2014 | 8 Pages |
Abstract
IND/GLY is cost-minimising vs INDÂ +Â GLY and dominates SFC in the maintenance treatment of COPD patients in Sweden. Encouraging dual bronchodilator therapy over an ICS-containing combination results in lower total costs and better outcomes compared to combination therapy including fluticasone in moderate-to-severe COPD patients with low exacerbation risk.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
David Price, Dorothy Keininger, Madlaina Costa-Scharplatz, Karen Mezzi, Maria Dimova, Yumi Asukai, Björn Ställberg,